


D. Burman,* A. K. Hodson,† C. B. S. Wood,‡ and N. F. W. Brueton
Bristol Royal Hospital for Sick Children and South West Regional Transfusion Centre, Bristol.

*Correspondence to Dr. D. Burman, Bristol Royal Hospital for Sick Children, Bristol BS2 8BJ.*

†Present address: City Hospital, Nottingham.
‡Present address: Queen Elizabeth Hospital for Children, London E.2.

**Short reports**

Since this report was written, 3 haemophiliacs have been reported to develop pulmonary oedema after transfusion of fresh frozen plasma and 1 of them died. I received a transfusion containing white cell antibodies and another Gm antibodies (Kernoff et al., 1972).

**REFERENCE**


**Addendum**

Since this report was written, 3 haemophiliacs have been reported to develop pulmonary oedema after transfusion of fresh frozen plasma and 1 of them died. I received a transfusion containing white cell antibodies and another Gm antibodies (Kernoff et al., 1972).

**REFERENCE**


**Magnesium supplementation in Bartter’s syndrome**

Bartter’s syndrome (hypokalaemic, hypochloraeic alkalosis, normotension, growth failure, and juxtaglomerular hyperplasia) is a rare disorder with less than 25 reported cases (Sutherland et al., 1970). There appear to be two forms of this syndrome. The mild form usually has its onset after the first year of life, presenting with electrolyte imbalance, growth failure, and weakness, and markedly improves with electrolyte correction (Beilin et al., 1967; Cannon et al., 1968; Greenberg et al., 1966). Those with the severe type have symptoms of lethargy, poor appetite, dehydration, seizures, failure to thrive from the early months of life, and usually succumb before 1 year of age (Sutherland et al., 1970; Walker, 1971). This report describes the apparent life-saving effects of magnesium supplementation in an infant with the severe form of Bartter’s syndrome.

**Case report**

An 11-week-old Black infant was admitted because of failure to thrive. He had been the 2·62 kg product of a term pregnancy. His unwed mother reported her gestation and delivery to have been uncomplicated. A 4-year-old half-brother and a 15-month-old sister are healthy. He had been apathetic, eating poorly, regurgitating, and had failed to gain weight from 3 weeks of age. On admission he weighed only 2·79 kg with a height of 54 cm. He was emaciated, apathetic, mildly febrile, and sweating. He showed severe muscle weakness and had essentially no head control, deep tendon reflexes were hypoactive, and there was no muscle twitching. Serum electrolytes showed him to have marked hypokalaemic, hypochloraeic alkalosis with a serum sodium 133 mEq/l., potassium 2·0 mEq/l., chloride 74 mEq/l., total carbon dioxide 40 mEq/l., and pH 7·62. The serum calcium, phosphorus, creatinine,
486

Short reports

amino acids, proteins, creatine phosphokinase, and a barium swallow were all normal. The 24-hour urinary excretions of potassium, sodium, and chloride were excessive in respect to serum electrolytes and exceeded dietary intake. Total body potassium as determined by the natural isotope method was found to be 25% below normal. Results of 11 serum magnesium determinations on different days ranged from 1.5 to 1.9 mEq/l with a mean of 1.7 mEq/l. His blood urea-nitrogen ranged between 30 and 40 mg/100 ml, and an ³¹P iodotholamate clearance was 39 cm²/min per 1.73 m² (normal adult range 90 to 120 cm²/min per 1.73 m²). IVP showed delayed visualization bilaterally. Renal biopsy (Fig.) showed cloudy swelling of the proximal tubules and marked hyperplasia of the juxtaglomerular apparatus. Plasma renin activity and aldosterone levels were raised fifteen- to fifty-fold on repeated determinations, though at no time was the patient hypertensive.

A diagnosis of Bartter’s syndrome was made and the subject was started on oral potassium chloride supplementation. In spite of correction of serum electrolytes and adequate caloric intake (140 to 160 cal/kg per 24 hours achieved by gavage) he continued to grow poorly, remained apathetic, hypotonic, and refused to eat. There was no clinical improvement after the addition of either supplemental sodium chloride or a combination of both sodium chloride and spironolactone (12.5 mg twice daily) to his diet; however, subsequent plasma renin and aldosterone levels fell conspicuously but remained raised (Table). Consequently, a muscle biopsy was performed and sodium and magnesium content estimated. The sodium was 91 mEq/kg fat-free wet weight (normal 33–43) and the magnesium was 11.6 mEq/kg fat-free wet weight (normal 20±1.8).

Because of the diminished muscle magnesium content, he was started on oral magnesium oxide therapy at a dosage of 30 mg MgO/kg body weight per day (6 mEq Mg/day). Within 48 hours, he showed a marked improvement in muscle tone and strength, good head control, and improved appetite, so that he no longer required gavage feedings. He gained weight at a rate of 25 g/day over the next 19 days and then reverted to his previous weight gain velocity of 10 g/day. The mean serum magnesium level increased to 1.9 mEq/l during the succeeding 6 weeks. Statistically, this level was significantly higher than the mean serum magnesium level before therapy (P <0.01). His mental and motor functions improved dramatically as reflected by advancement in developmental milestones.

At 9 months of age he developed an intercurrent enteritis and magnesium oxide was discontinued for 3 days. During this interval, the other electrolyte supplementations were continued and normal serum electrolyte values were maintained; however, he became hypotonic, unable to sit, apathetic, and refused to eat. After the reinstitution of magnesium oxide therapy there was again rapid improvement in his appetite and motor tone. A repeat muscle biopsy at 10 months of age showed a normal magnesium concentration (19.8 mEq/kg fat-free wet weight) but no change in the sodium content. Now at 16 months he is progressing satisfactorily on magnesium 30 mg/kg per 24 hours, potassium chloride 28 mEq/24 hours (both given in divided dosage 4 times daily), and spironolactone 12.5 mg twice daily.

Discussion

Hypomagnesaemia has not been a consistent feature of Bartter’s syndrome, and was not observed at any time in the present case. However, a total body depletion of magnesium, with a decrease in intracellular concentrations, can occur in the presence of normal serum levels (MacIntyre et al., 1961; Martin, 1969). The use of supplemental magnesium in Bartter’s syndrome with hypomagnesaemia has previously been described by Sutherland and co-workers (Sutherland et al., 1970) in two subjects who died before the influence of this therapy could be ascertained. Hyperaldosteronism is associated with excessive urinary excretion of magnesium, and a negative balance for this element (Wacker and Parisi, 1968; Horton and Biglieri, 1962); therefore, patients with Bartter’s syndrome may be at particular risk from magnesium deficiency. Measurements of muscle magnesium in Bartter’s

<table>
<thead>
<tr>
<th>Dietary supplement</th>
<th>Plasma renin activity (ng/ml per hr)</th>
<th>Plasma aldosterone (pg/ml)</th>
<th>Serum Na (mEq/l)</th>
<th>Serum K (mEq/l)</th>
</tr>
</thead>
<tbody>
<tr>
<td>None</td>
<td>750</td>
<td>8956</td>
<td>133</td>
<td>2·0</td>
</tr>
<tr>
<td>KCl</td>
<td>223</td>
<td>10,619</td>
<td>134</td>
<td>4·6</td>
</tr>
<tr>
<td>KCl + NaCl</td>
<td>125</td>
<td>4294</td>
<td>147</td>
<td>4·7</td>
</tr>
<tr>
<td>KCl + NaCl + MgO</td>
<td>137</td>
<td>1907</td>
<td>144</td>
<td>3·8</td>
</tr>
<tr>
<td>KCl + MgO</td>
<td>84</td>
<td>1503</td>
<td>140</td>
<td>4·1</td>
</tr>
</tbody>
</table>

Note: Normal adult fasting reclining PRA ranges from 0·2–3·6 ng/ml per hr, and normal adult fasting reclining aldosterone levels range from 32–200 pg/ml.
syndrome have not been reported previously; the low intracellular magnesium concentration found in this patient suggests that magnesium deficiency may be more common in Bartter's syndrome than indicated by serum magnesium levels alone.

Anorexia, apathy, and muscle weakness are common features of magnesium deficiency (Shils, 1969); all of these were present in our patient and improved after the introduction of dietary magnesium supplementation. The fever and excessive sweating also disappeared with magnesium supplementation. These are not recognized manifestations of magnesium deficiency; however, it is interesting to note that magnesium administration is effective in reducing the fever and sweating that occurs in patients with osteogenesis imperfecta (Solomons and Stynker, 1969). Before the magnesium therapy, his progressive clinical course was in keeping with the severe type of Bartter's syndrome; now, at 16 months of age, he is progressing normally apart from a diminished growth velocity. This course is most unusual for subjects with the severe infantile type of disease. It is concluded that intracellular depletion of magnesium may be responsible for at least some of the severe features of this disease which do not respond to more conventional therapy, and that measurement of muscle magnesium and/or a prolonged trial of magnesium supplementation should be undertaken in all subjects with the severe type of Bartter's syndrome.

Summary

Intracellular magnesium deficiency, with normal serum magnesium levels, was shown in an infant with the severe type of Bartter's syndrome. After the introduction of oral magnesium therapy, there was marked improvement in appetite and in muscle tone and strength; the intramuscular concentration of magnesium increased to a normal level. At 16 months he was progressing normally apart from a diminished growth velocity, and has had an unusually prolonged survival. It is concluded that intracellular magnesium depletion may contribute to the clinical manifestations and fatal course of this disease.

This study was supported by grants from the Human Growth Foundation and the General Clinical Research Centers Program of the Division of Research Resources, National Institutes of Health (RR-69). Also supported in part by USPHS Grant No. RO1-AM12432 from NIHAMD, and by Agricultural Research Service, U.S. Department of Agriculture, Grant No. 12-14-100-9941 (61).

REFERENCES


JOHN W. MACE,* K. MICHAEL HAMBIDGE,† RONALD W. GOTTLIN, REUBEN S. DUBOIS, CLIVE S. SOLOMONS, and FRED H. KATZ

Department of Pediatrics, University of Colorado School of Medicine, and Veterans Administration Hospital, Denver, Colorado, U.S.A.

*Present address: Loma Linda University School of Medicine, Loma Linda, California, U.S.A.
†Correspondence to Dr. Kenneth Michael Hambidge, University of Colorado Medical Center, 4200 East Ninth Avenue, Denver, Colorado 80220, U.S.A.

Generalized hypermobility of joints

Arthrochalasis multiplex congenita

Generalized hypermobility of joints has been reviewed by Hass and Hass (1958) who described 5 patients in detail and called the condition arthrochalasis multiplex congenita; they noted that little attention had been paid previously to the orthopaedic manifestations and stressed that generalized hypermobility could exist without skin laxity; they suggested that it was an entity separable from Ehlers-Danlos syndrome and that joint involvement was very variable.

Carter and Sweetnam (1960) showed the strong...
Magnesium supplementation in Bartter's syndrome.

J W Mace, K M Hambidge, R W Gotlin, R S Dubois, C S Solomons and F H Katz

Arch Dis Child 1973 48: 485-487
doi: 10.1136/adc.48.6.485

Updated information and services can be found at:
http://adc.bmj.com/content/48/6/485.citation

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/